NVIV Invivo Therapeutics Holdings Corp

Price (delayed)

$0.757

Market cap

$25.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.35

Enterprise value

$2.11M

Highlights
NVIV's equity has surged by 167% year-on-year and by 33% since the previous quarter
NVIV's EPS has surged by 99% year-on-year and by 73% since the previous quarter

Key stats

What are the main financial stats of NVIV
Market
Shares outstanding
34.26M
Market cap
$25.94M
Enterprise value
$2.11M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$8.88M
EBITDA
-$8.54M
Free cash flow
-$9.07M
Per share
EPS
-$0.35
Free cash flow per share
-$0.31
Book value per share
$0.75
Revenue per share
$0
TBVPS
$0.94
Balance sheet
Total assets
$27.68M
Total liabilities
$2.16M
Debt
$941,000
Equity
$25.52M
Working capital
$24.04M
Liquidity
Debt to equity
0.04
Current ratio
17.3
Quick ratio
16.79
Net debt/EBITDA
2.79
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-48.8%
Return on equity
-56.8%
Return on invested capital
-445.1%
Return on capital employed
-33.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVIV stock price

How has the Invivo Therapeutics Holdings stock price performed over time
Intraday
4.59%
1 week
-2.95%
1 month
0.93%
1 year
-54.12%
YTD
-6.54%
QTD
-23.54%

Financial performance

How have Invivo Therapeutics Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.89M
Net income
-$8.88M
Gross margin
N/A
Net margin
N/A
NVIV's net income is up by 23% year-on-year and by 2.1% since the previous quarter
Invivo Therapeutics Holdings's operating income has increased by 20% YoY and by 2.2% QoQ

Growth

What is Invivo Therapeutics Holdings's growth rate over time

Valuation

What is Invivo Therapeutics Holdings stock price valuation
P/E
N/A
P/B
1.01
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NVIV's EPS has surged by 99% year-on-year and by 73% since the previous quarter
NVIV's equity has surged by 167% year-on-year and by 33% since the previous quarter
NVIV's P/B is 56% below its 5-year quarterly average of 2.3

Efficiency

How efficient is Invivo Therapeutics Holdings business performance
NVIV's return on equity has surged by 59% year-on-year and by 27% since the previous quarter
Invivo Therapeutics Holdings's ROA has soared by 51% YoY and by 23% from the previous quarter
NVIV's return on invested capital is up by 8% year-on-year

Dividends

What is NVIV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVIV.

Financial health

How did Invivo Therapeutics Holdings financials performed over time
The total assets has soared by 123% YoY and by 26% from the previous quarter
Invivo Therapeutics Holdings's current ratio has soared by 74% from the previous quarter
The debt is 96% less than the equity
NVIV's equity has surged by 167% year-on-year and by 33% since the previous quarter
The debt to equity has plunged by 69% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.